CORP BRIEF: Samaiden, Kanger and Ho Wah

by TMR / graphic by MZUKRI MOHAMAD

Former CEO, wife to be charged over false claims

A FORMER CEO with the title Datuk and his wife are to face charges at the Shah Alam Sessions Court today relating to making false claims and committing criminal breach of trust (CBT) involving RM140 million over a period of five years from 2013. According to a source from the Malaysian Anti-Corruption Commission (MACC), the couple, aged 63, was detained at about 9.40am yesterday at MACC headquarters in Putrajaya. The source said the Datuk will be facing a number of charges for making false claims involving about RM8 million and CBT involving about RM132 million from 2013 until 2017. Meanwhile, his wife is expected to face the charge of abetting him in committing the offences. — Bernama

Samaiden secures RM115.6m contract from BTM

SAMAIDEN Group Bhd’s wholly owned subsidiary, Samaiden Sdn Bhd, secured a RM115.6 million contract from BTM Resources Bhd’s wholly owned subsidiary, BTM Biomass Products Sdn Bhd, to develop a biomass renewable energy (RE) power plant in Terengganu. In a bourse filing yesterday, Samaiden said it received and accepted the engineering, procurement, construction and commissioning works in relation to the development of a 10MW biomass RE power plant at Lot 153-C, Mukim Hulu Chukai in Teluk Kalong. It added that works will commence on Jan 2, 2021, and the completion date is targeted within 23 months.

NIBM approves Kanger’s vaccines distribution

KANGER International Bhd announced that the National Institutes of Biotechnology Malaysia (NIBM) issued a letter stating that NIBM has no objections for Kanger to communicate with relevant stakeholders at China National Pharmaceutical Group Corp (Sinopharm) to purchase Covid-19 vaccines for private-sector use in Malaysia. In a filing to Bursa yesterday, Kanger said this is a positive step in its efforts to commence the distribution of Sinopharm’s Covid-19 vaccines in Malaysia. Sinopharm has developed two Covid-19 vaccines, which have already entered Phase 3 trials before being approved for general use in more than 10 countries.

MDA approves Ho Wah’s Covid-19 test kit

HO WAH Genting Bhd was granted a special access approval to distribute the Wuhan PCR test kit in Malaysia by the Medical Device Authority (MDA). In an exchange filing yesterday, the group said it also received the first purchase order from Gnosis Laboratories (M) Sdn Bhd for e-diagnosis Covid-19 nucleic acid test kit manufactured by Wuhan Easydiagnosis Biomedicine Co Ltd. The approval will allow HWGB Biotech Sdn Bhd to market and sell the Wuhan PCR test kit to Gnosis in Malaysia.